This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Ligand (LGND) to Spin Out Pelican Subsidiary, Updates '23 View
by Zacks Equity Research
Ligand (LGND) intends to spin out and merge its subsidiary Pelican with Primordial Genetics to form a new standalone company. Post-merger, it will own a 49.9% stake in this new company.
Ligand Pharmaceuticals (LGND) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) closed the most recent trading day at $62.56, moving +0.94% from the previous trading session.
Ligand Pharmaceuticals (LGND) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) closed the most recent trading day at $62.71, moving -1.45% from the previous trading session.
Ligand (LGND) Down 8.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ligand (LGND) Up 4% on Raised '23 EPS, Beats on Q2 Earnings
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) reports second-quarter results as earnings beat the estimates, but sales miss the mark. Management raises the 2023 financial outlook.
Ligand (LGND) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Ligand (LGND) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ligand Pharmaceuticals (LGND) Q2 Earnings Beat Estimates
by Zacks Equity Research
Ligand (LGND) delivered earnings and revenue surprises of 86.84% and 5.85%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Drug, Biotech Stocks' Q2 Earnings on Aug 8: LLY, LGND & More
by Kinjel Shah
Let us look at five drug/biotech companies, LLY, LGND, NVAX, EBS and BLUE, which are gearing up for their earnings release.
Ligand (LGND) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
Ligand's (LGND) second-quarter 2023 performance is likely to have been driven by rising royalty revenues on the back of higher growth in sales of drugs developed using its pelican platform.
AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Ligand Pharmaceuticals (LGND) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Ligand Pharmaceuticals (LGND) closed at $66.56, marking a -1.35% move from the previous day.
Cadence Design and Ligand have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Cadence Design and Ligand have been highlighted as Zacks Bull and Bear of the Day.
Bear of the Day: Ligand Pharmaceuticals (LGND)
by Kevin Cook
Ligand is an innovative Bio-Pharma M&A royalty-generator, but the model is volatile
Ligand Pharmaceuticals (LGND) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) closed the most recent trading day at $68.13, moving -0.92% from the previous trading session.
Ligand (LGND) Offers $15M in Cash to Acquire All Novan Assets
by Zacks Equity Research
Ligand (LGND) announces a $15 million bid in cash to acquire all assets of Novan Inc. along with another $15 million loan as debtor-in-possession financing.
Ligand Pharmaceuticals (LGND) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) closed the most recent trading day at $68.76, moving +1.34% from the previous trading session.
Frequency (FREQ) Up 77% on Merger Deal With Korro Bio
by Zacks Equity Research
Post-merger, Frequency (FREQ) focuses on advancing RNA editing programs. This combined entity is set to operate under the name Korro Bio, which will apply to trade on the NASDAQ under the ticker symbol KRRO.
Gilead's (GILD) Veklury Gets FDA Nod for Label Expansion
by Zacks Equity Research
Gilead's (GILD) antiviral treatment Veklury (remdesivir) has now been approved for the treatment of COVID-19 patients with severe renal impairment, including those on dialysis.
Eli Lilly (LLY) to Buy Versanis, Strengthen Obesity Portfolio
by Zacks Equity Research
For the purchase of Versanis, Lilly (LLY) agrees to pay up to $1.93 billion in cash.
Perrigo (PRGO) Gets FDA Nod for First OTC Birth Control Pill
by Zacks Equity Research
Following the FDA approval, Perrigo's (PRGO) Opill is the first ever over-the-counter birth control pill. The drug will be made available in the United States early next year.
First Wave (FWBI) Down 32% on Cystic Fibrosis Study Setback
by Zacks Equity Research
Initial data from First Wave's (FWBI) mid-stage study evaluating its investigational oral capsule in cystic fibrosis patients did not likely meet its primary endpoint.
Here's Why Investors Should Add Encompass Health (EHC) to Portfolio
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of solid demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.
Incyte's (INCY) Opzelura Meets Goal in Phase III Pediatric Study
by Zacks Equity Research
Incyte's (INCY) Opzelura (ruxolitinib cream) meets the primary endpoint in a phase III study in children with atopic dermatitis.
Ligand Pharmaceuticals (LGND) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Ligand Pharmaceuticals (LGND) closed the most recent trading day at $69.49, moving -0.52% from the previous trading session.
Roche (RHHBY) Blood Cancer Drug Columvi Wins EC Approval
by Zacks Equity Research
Roche's (RHHBY) blood cancer portfolio gets a boost with the EC's approval of Columvi (glofitamab-gxbm) for treating patients with R/R DLBCL.